ABSTRACT
INTRODUCTION
In children with acute lymphoblastic leukemia (ALL) who bear certain presenting features, such as a white cell count above 50,000 per cubic millimeter an age of 10 years or older, the presence of bulky disease, T-celllineage immunophenotype and various chromosomal translocations carry an increased risk of treatment failure. [1] [2] [3] [4] [5] The outcome for most of these children has improved with the use of intensive chemotherapy after the induction of remission, but approximately 30 percent of such high-risk patients eventually relapse. [5] [6] [7] [8] Numerous studies have demonstrated that a rapid response to initial chemotherapy is an important prognostic factor in childhood ALL. [6] [7] [8] [9] German investigators observed that patients with fewer than 1000 blasts per cubic millimeter in the peripheral blood after a seven-day course of prednisone had significantly better event free survival than patients with 1000 or more blasts per cubic millimeter. 10, 11 Similarly, it is reported that children with 25% blasts or fewer in the bone marrow on day seven had a better response to initial chemotherapy (three-year eventfree survival, 77%) than those with more than 25% blasts (three-year event-free survival, 48%). 11 In an attempt to improve the outcome for children with a slow response to initial therapy, we follow a strategy of augmented, intensive post-induction chemotherapy that was based on previous successful regimens for ALL. 6, 12, 13 This approach appeared promising in a nonrandomized pilot study. We now report Original Article on a randomized comparison of augmented therapy with standard intensive post induction therapy in children with high-risk ALL who entered remission after a slow response to initial therapy.
METHODS

Patients
Children with newly diagnosed ALL who were one to nine years of age and had white cell counts of at least 50,000 per cubic millimeter or who were 10 years of age or older were enrolled between January 2005 and December 2011. Those with lymphomatous features were excluded. Diagnosis was based on morphologic, biochemical, and immunologic features of leukemic cells, including lymphoblast morphology as determined by Wright Giemsa staining, negative staining for myeloperoxidase, and reactivity with monoclonal antibodies to lymphoid differentiation antigens associated with B-cell or T-cell lineage, Patients with slow initial responses (more than 25% marrow blasts on day seven) who had entered remission by day 28 were randomly assigned at the end of induction therapy to receive standard or augmented therapy.
Treatment Protocol
All patients received identical five week courses of induction chemotherapy, withUK-ALLX1 protocol. The post induction regimens are with Standard therapy and Augmented Berlin Frankfurt Munster therapy given (Fig 1) . 14, 15 Therapy was continued for two years for girls and for three years for boys, beginning with the first interim maintenance period (Fig 1) . Pre-symptomatic central nervous system therapy consisted of intrathecal methotrexate and cranial radiation. Informed consent was obtained from the patients, their parents, or both, as deemed appropriate, according to rules of the University.
Study Design and Statistical Analysis
Balanced block randomization was used to ensure that approximately equal numbers of patients were randomly assigned to each regimen. The study was monitored by an independent data monitoring committee and followed a monitoring plan that was based on group sequential monitoring boundaries that required analysis of results at six month intervals for a maximum of 10 analyses. 16 With a target enrollment of 296 randomized patients, we estimated that the study had a power of approximately 81 percent at the final analysis to detect a change in five year event free survival from 45 %to 62 % or more with a two sided log rank test (alpha level, 0.05).
Similarities between patients in the two groups were assessed with chi square tests for homogeneity of proportions. Outcome analyses used life table methods and associated statistics. The primary end point examined was event free survival from the time of randomization. The events considered were relapse at any site, death during remission, or a second malignant neoplasm, which ever occurred first. Data on patients who had not had an event at the time of the analysis were censored in the analysis of event free survival at the time of last contact with them. Life table estimates were calculated by Kaplan-Meier procedure, and the standard deviation of the life table estimate was obtained with Greenwood's formula. 17 The Kaplan-Meier estimates (±SD) are presented for either the first five years or the first three years after randomization, depending on the number of patients in follow up. Ninety five percent confidence intervals can be approximated as the life table estimates ±1.96 SD. The log rank statistic was used to compare patterns of event free survival and overall survival in the groups. 18, 19 Comparisons of randomized treatment regimens were performed according to the intention to treat method. Stratified log rank tests were also used to adjust for the possible modifying effect of other factors on the comparison of interest. 20 An adjusted Cox regression analysis was used to determine the influence of prognostic factors on the primary treatment effect. Life table analyses of the effect of isolated central nervous system and marrow relapses on the results with each regimen were compared with the log rank statistic. Life table analysis of the relative risk of an adverse event was calculated with the log rank ratio of observed events to expected events.
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RESULTS
Patients
A total of 1136 patients were enrolled. Three patients died before day seven, and marrow was not obtained on day seven from 15 patients. Of the remaining 1118 patients, 360 (32%) had slow responses to initial therapy. Of these, The characteristics of the patients in the two groups are shown in Table 1 . There were no significant differences between the groups. Most patients were at least 10 years of age, and approximately half had white cell counts of at least 50,000 per cubic millimeter. Among 209 patients with immunophenotypic data, 87.6% had ALL of B cell lineage.
Outcome of Treatment
The four year event free survival rate was significantly better among patients in augmented therapy group than among those in standard therapy group (75.4±4.0 vs. 57.2±4.5%, P=0.009, adjusted for multiple evaluations of the data).
At that time the median follow up for patients with event free survival was 31 months (range, 1 to 63). After an additional follow up period of approximately 1.5 years, five year event free survival remained significantly better in the augmented therapy group than in the standard therapy group (75.0±3.8 vs. 55.0±4.5 percent, P<0.001) (Fig 2) . The median follow up for patients with event free survival was 49 months (range, 2 to 82 months). The difference in event free survival was maintained (P<0.001) when patients who received a bone marrow transplant were censored at the time of transplantation. Overall survival at five years was also better in the augmented therapy group than in the standard therapy group (78.4±3.7 vs. 66.7±4.2 percent, P=0.02).
There were 65 events in the standard therapy group and 36 events in the augmented therapy group (Table 2) . Isolated marrow relapse was the main cause of treatment failure for both regimens, occurring in 43 patients in the standard therapy group and 30 patients in the augmented therapy group (P= 0.004 by the log rank test), whereas central nervous system relapses were more common among patients in the standard therapy group (8 vs. 0, P=0.002 by the log rank test). Seven patients in the standard therapy group and four patients in the augmented therapy group died while in remission.
In all subgroups analyzed, the results were better among patients who received augmented therapy than among those who received standard therapy. The difference in outcome between groups was most pronounced for patients who were one to nine years of age, all of whom had high white cell counts as dictated by the eligibility criteria, with five year event free survival of 41.7±8.4 % in the standard therapy group and 84.6±5.0 % in the augmented therapy group (P<0.001) ( Figure 3 ) and a relative risk of an adverse event in the standard therapy group of 4.6. For patients who were 10 or more years old with white cell counts of at least 50,000 per cubic millimeter, the outcome was better after augmented therapy than after standard therapy (three year event free survival, 66.7±9.7 vs. 47.9±9.7%) (Figure 3) 
Prognostic Factors
An analysis of prognostic factors for the entire cohort of patients indicated that most base line characteristics did not influence event free survival. However, a white cell count of 200,000 per cubic millimeter or higher, race other than black or white, and the presence of a t(9;22) translocation were prognostically important. For patients with white cell counts of at least 200,000 per cubic millimeter, three year event free survival was 47.4±9.1%, as compared with 72.4±2.7% for those with white cell counts below 200,000 per cubic millimeter (P=0.004). A Cox regression analysis with adjustment for these and other common prognostic factors revealed no attenuation of the effect of treatment on the difference in outcome between the augmented therapy and the standard therapy groups (P=0.001).
Toxic Effects
The toxic effects of the two types of therapy are shown in Table 3 . There was a higher frequency of allergic reactions to Escherichia coli asparaginase in the augmented therapy group than in the standard therapy group (64 vs. 4 reactions). Osteonecrosis developed in 20 patients in the augmented therapy group and in 14 patients in the standard therapy group; only one of these patients was under 10 years of age at the time of diagnosis. Life table estimates for the occurrence of osteonecrosis at three years were 15.1% for the augmented therapy group and 11.9% for the standard therapy group (P=0.44). No cases had developed after three years of follow up. The mean total duration of hospitalization was slightly longer for patients in the augmented therapy group than in the standard therapy group, primarily because of the additional time needed for the second cycles of interim maintenance and delayed intensification therapy (data not shown).
Three patients in the augmented therapy group died in remission as a result of toxicity: one died of acute respiratory distress syndrome, one of pulmonary toxicity, and one of Candida tropicalis infection; one patient in remission was murdered. Seven patients in the standard therapy group died in remission. Four of these deaths were due to documented infection: aspergillosis in one patient, clostridium septicemia in one, hepatosplenic candidiasis in one, and infection with unspecified gram negative bacteria in one. Of the remaining three deaths, one was due to pulmonary hemorrhage, one was due to acute respiratory distress syndrome after a presumed infection, and one was due to unknown causes.
DISCUSSION
It previously was reported that among children with high risk ALL, those with a rapid response to initial therapy (defined as the presence of no more than 25 % blasts in the marrow on the seventh day of induction chemotherapy) had a better outcome than those with a slow response (more than 25 percent blasts). 9, 11, 22 Other investigators also reported poor outcomes for patients with a slow response to prednisone or multiagent induction therapy. 6, 10, 15, 23 In this randomized trial of post induction treatment of patients with a slow response, we found that the outcome with augmented treatment was superior to that with standard treatment (five year event free survival, 75% vs. 55%). In our nonrandomized pilot study of augmented therapy, the four year event free survival rate (±SD) was 70.8±4.6%. 14 Furthermore, subsequent analysis of the pilot study revealed a six year event free survival rate of 65.4±4.9%, suggesting that the results of the randomized trial are unlikely to change significantly with longer follow up. Our results also suggest that the degree of cytoreduction achieved after one to two weeks of induction chemotherapy is a useful indicator of the susceptibility of leukemic cells to chemotherapeutic drugs. 10, 15 Augmented treatment significantly improved event free survival overall (75.0±3.8%, as compared with 55.0±4.5% in the standard therapy group). In all subgroups analyzed, augmented therapy resulted in improved event free survival. The difference was significant in the subgroup of patients who were one to nine years of age, all of whom had high white cell counts. There was a trend toward a better outcome among older patients. There was also a trend toward improved outcomes with augmented therapy in patients with ALL of either B cell lineage or T cell lineage. This finding is in agreement with our analysis, which demonstrated improved outcome for the entire cohort of children with T cell-lineage ALL who were treated with Children's Cancer Group protocols between 1989 and 1995. 24 Augmented therapy was ineffective for the seven patients with the Philadelphia chromosome. Five of these seven patients had events, and four of them ultimately died. The two patients who survived without events received a bone marrow transplant while in first remission. These data are consistent with recent data from European studies of children with ALL who have a poor response to initial prednisone therapy. 25 The toxic effects of augmented therapy have been considerable, but they appear to be manageable. The most common long term toxic effect was osteonecrosis, which occurred almost exclusively in adolescent patients.
We noted a significantly lower rate of central nervous system relapse in the augmented therapy group than in the standard therapy group. Since the patients assigned to each regimen received cranial radiotherapy and intrathecal therapy for presymptomatic treatment of central nervous system, the benefit observed with augmented therapy may have been due to the use of intensified systemic therapy. Indeed, previous investigators have noted a similar effect with intensive systemic therapy. [26] [27] [28] . Although we do not know which components of augmented therapy were responsible for the improved outcome, we surmise that the effect is attributable to the increased dose intensities and prolonged duration of therapy. During the interim maintenance phase in the augmented therapy regimen, repeated courses of vincristine, intravenous methotrexate, and asparaginase replaced the daily oral mercaptopurine and the weekly oral methotrexate used in the standard therapy regimen. The augmented regimen also included an additional two weeks of nonmyelosuppressive therapy with vincristine and asparaginase during each consolidation or reconsolidation course and included both a second interim maintenance phase and a second course of delayed intensification.
A recent Children's Cancer Group study of intermediate risk ALL showed that patients with a slow response had an improved outcome when treated with two courses of delayed intensification rather than one course, suggesting that prolonged therapy was important to the improved outcome with augmented therapy in the current study. 28 We are attempting to distinguish the relative contributions of early increased dose intensity and a prolonged duration of therapy in a new therapeutic study of children with high risks ALL.
CONCLUSION
Augmented post-induction chemotherapy results in an excellent outcome for most patients with high-risk ALL
